Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

ps, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Ale Gicqueau, ... Chen, Director of Clinical Affairs at Align Technology, on ... at the upcoming ACRP 2015 Global Conference and Exhibition ... City, Utah. , During the poster presentation, Ale ... creating and running a Postmarket Registry, the requirements and ...
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... as a result of recent discussions with certain shareholders ... of the Company, after dealing with certain matters including ... meeting of shareholders on March 26, 2015 (the "Meeting") ... election of directors will take place when the Meeting ...
(Date:3/25/2015)... 25, 2015 Laboratory workers can ... and Analytical Balances to get best-performing features while ... weighing balances from the trusted brand include: , ... increase your efficiency by providing a large weighing ... Weighing modes include parts counting, percent weighing, checkweighing, ...
Breaking Biology Technology:Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2
... Dec. 5 Representatives from over 40,Shanghai ... attendance, took,part in the first annual Cinpathogen ... hosted by Cinpathogen Inc. and chaired by,Professor ... Epidemiology,Institute, covered current developments in clinical laboratory ...
... ( http://www.CMELLC.com ),a leading provider of fully accredited ... new structure and management team,put in place to ... address the educational needs of healthcare professionals moving,forward., ... role of senior vice,president and general manager, and ...
... $8.1 Million Financing in Connection ... Reverse Stock Split Planned for January 2008, ... today announced that the Company has:, - Signed an agreement ... based in Israel. The acquisition,is expected to close tomorrow. The initial ...
Cached Biology Technology:Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference 2CME LLC Restructures, Announces Its New Executive Management Team 2Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... 2015 In Brazil , cloud ... using these solutions and 42 percent planning to invest in ... 25 percent of the companies will be investing in these ... of companies in the region are currently opting for the ... will command significant attention in the coming years. This trend ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... ROCKVILLE, Maryland July 9, 2009 Human ... the New England Journal of Medicine of ... showed the life-saving potential of the Company,s human monoclonal ... of human safety studies, which supported the use of ...
... appearing in Environmental Health Perspectives (EHP) ... for the Project on Emerging Nanotechnologies (PEN), focuses ... It provides an overview of current practices; ... safety implications; and possible future directions for nanoremediation. ...
... Van Andel Research Institute (VARI) investigators have ... target in the treatment of the most aggressive forms ... few treatment options. "Breast cancer mortality rates are ... traditional treatments tend to be more aggressive and have ...
Cached Biology News:Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax 2Contaminated site remediation: Are nanomaterials the answer? 2Possible drug target found for one of the most aggressive breast cancers 2